VIVUS (VVUS) has an average broker rating of 2.67, which is interpreted as a Hold, as rated by 3 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy. 1 considers that the stock is a Sell.
VIVUS Inc. has lost 0.94% in the last five trading days and dropped 5.41% in the last 4 weeks. VIVUS Inc. has dropped 14.63% during the last 3-month period . Year-to-Date the stock performance stands at 2.94%. VIVUS (NASDAQ:VVUS): On Tuesdays trading session , Opening price of the stock was $1.06 with an intraday high of $1.08. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.05. However, the stock managed to close at $1.05, a loss of 0.94% for the day. On the previous day, the stock had closed at $1.06. The total traded volume of the day was 102,420 shares.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.